Press "Enter" to skip to content

Europe Diabetes Drugs Market Size 2019 – Industry Analysis by Types, Applications, Key Players, and leading Countries Forecast to 2024

Europe Diabetes Drugs

The “Europe Diabetes Drugs Market” report 2019 delivers up-to-date information about market changes and prospective threats, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. Moreover, it focuses on the cost-saving aspects of procurement and on providing insights that can lead to optimization of category spend.

Get a Sample Copy of the Report At – https://www.industryresearch.co/enquiry/request-sample/14099072

Market Overview:

  • – The European diabetes drug market is expected to record a high CAGR of 5.68% during the forecast period (2019 – 2024) due to the growing prevalence of diabetes, growing geriatric population levels, unhealthy diet, and increasing levels of physical inactivity.
  • – Diabetes is becoming an increasingly common health condition, which can disable patients and potentially lead to fatal health complications.
  • – Europe’s diabetes spending is approx. 9% of the total global healthcare expenditure; expenditure on diabetes largely varies among countries in Europe. It ranges from EUR 312 per-capita in the Republic of Macedonia to EUR 6,896 per-capita in Norway.
  • – Similarly, prevalence is also widely varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular diseases, blindness, kidney failure, and lower limb amputation.
  • – Currently, 30 countries out of 47 are implementing a national plan that includes diabetes individually or within a plan for non-communicable diseases (NCDs).
  • – Another ten have announced such plans for the near future. The remaining seven either have joined an international initiative on diabetes, or adopted a political resolution, or are covering diabetes in their national health plans. An increasing number of countries are moving toward plans for NCDs, rather than plans addressing diabetes alone. However, European countries still have to implement a fully comprehensive, multi-sectoral approach to diabetes, including factors from outside the health sector within their diabetes policies.

    Top Key Players of Europe Diabetes Drugs Market Are:

  • Takeda
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck and Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Sanofi

    Reasons to buy:

    • In-depth analysis of the market on the global and regional level.
    • Major changes in market dynamics and competitive landscape.
    • Segmentation on the basis of type, application, geography and others.
    • Historical and future market research in terms of size, share, growth, volume & sales.
    • Major changes and assessment in market dynamics & developments.
    • Industry size & share analysis with industry growth and trends.
    • Emerging key segments and regions
    • Key business strategies by major market players and their key methods.
    • The research report covers size, share, trends and growth analysis of the Europe Diabetes Drugs Market on the global and regional level.

    Inquire or Share Your Questions If Any Before the Purchasing This Report – https://www.industryresearch.co/enquiry/pre-order-enquiry/14099072

    Scope of the Report:

  • The market is segmented by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by Segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), and by Geography.

    Europe Diabetes Drugs market covers the outlook for overall market status, size and share. The report provides complete coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Europe Diabetes Drugs market report also presents the market competition landscape and a corresponding detailed analysis of the major vendor in the market. 

    Key Market Trends:

    Oral Anti-diabetic Drugs and Insulin hold a Significant Market Share

    – Among the diabetes drugs in the European region, oral anti-diabetic and insulin drugs occupy a significant market share.
    – Of the insulin drugs, basal insulins subsegment’s market size is high due to high market penetration. Insulin glargine is the most widely used drug, and it has quite a few biosimilars in the market.
    – SGLT-2 inhibitors and DPP-4 inhibitor drugs are expected to gain a significant market share and record a high CAGR of more than 15% during the forecast period.

    Germany & France Alone Occupy More than 30% of Share in European Diabetes Drugs Market

    – Among the studied countries, Germany is expected to lead the market studied, with a considerable market share of 22%, followed by France.
    – In the GLP-1 segment, Victoza holds the largest market share in the European region, and a similar trend is being observed in Germany as well. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells and suppressing inappropriate elevated glucagon secretion.
    – The German generics market is vast, and the market for oral anti-diabetic drugs is expected to increase during the forecast period. However, pricing is a major issue in Germany, and many companies have backed-up with their plan to launch insulin in the country.
    – In France, the oral DPP-4 drugs dominate the market, followed by GLP-1 and Insulin.

    Europe Diabetes Drugs Market Report contents include:

    – Analysis of the Europe Diabetes Drugs market including revenues, future growth, market outlook

    – Historical data and forecast

    – Regional analysis including growth estimates

    – Analyzes the end user markets including growth estimates.

    – Profiles on Europe Diabetes Drugs including products, sales/revenues, and market position

    – Market structure, market drivers and restraints.

    Purchase this Report (Price 4000 USD for a Single-User License) – https://www.industryresearch.co/purchase/14099072

    Detailed TOC of Europe Diabetes Drugs Market Report Are:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Oral Anti-diabetic Drugs
    5.1.1.1 Biguanide (Value and Volume 2012-2024)
    5.1.1.1.1 Metformin
    5.1.1.2 Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
    5.1.1.2.1 Alpha – Glucosidase Inhibitors
    5.1.1.3 Dopamine – D2 Receptor Agonist (Value and Volume 2012-2024)
    5.1.1.3.1 Bromocriptin (Cycloset)
    5.1.1.4 Sodium – Glucose Cotransport – 2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
    5.1.1.4.1 Invokana (Canagliflozin)
    5.1.1.4.2 Jardiance (Empagliflozin)
    5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    5.1.1.4.4 Suglat (Ipragliflozin)
    5.1.1.5 Dipeptidyl peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
    5.1.1.5.1 Januvia (Sitagliptin)
    5.1.1.5.2 Onglyza (Saxagliptin)
    5.1.1.5.3 Tradjenta (Linagliptin)
    5.1.1.5.4 Vipidia/Nesina (Alogliptin)
    5.1.1.5.5 Galvus (Vildagliptin)
    5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)
    5.1.1.6.1 Sulfonylureas
    5.1.1.7 Meglitinide (Value and Volume 2012-2024)
    5.1.1.7.1 Meglitinide
    5.1.2 Insulin
    5.1.2.1 Basal or Long-acting Insulins
    5.1.2.1.1 Lantus (Insulin Glargine)
    5.1.2.1.2 Levemir (Insulin Detemir)
    5.1.2.1.3 Toujeo (Insulin Glargine)
    5.1.2.1.4 Tresiba (Insulin Degludec)
    5.1.2.1.5 Basaglar (Insulin Glargine)
    5.1.2.2 Bolus or Fast-acting Insulins
    5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    5.1.2.2.2 Humalog (Insulin Lispro)
    5.1.2.2.3 Apidra (Insulin Glulisine)
    5.1.2.3 Traditional Human Insulins
    5.1.2.3.1 Novolin/Actrapid/Insulatard
    5.1.2.3.2 Humilin
    5.1.2.3.3 Insuman
    5.1.2.4 Biosimilar Insulins
    5.1.2.4.1 Insulin Glargine Biosimilars
    5.1.2.4.2 Human Insulin Biosimilars
    5.1.3 Non-insulin Injectable Drugs
    5.1.3.1 GLP1 Receptor Agonists
    5.1.3.1.1 Victoza (Liraglutide)
    5.1.3.1.2 Byetta (Exenatide)
    5.1.3.1.3 Bydureon (Exenatide)
    5.1.3.1.4 Trulicity (Dulaglutide)
    5.1.3.1.5 Lyxumia (Lixisenatide)
    5.1.3.2 Amylin Analogue
    5.1.3.2.1 Symlin (Pramlintide)
    5.1.4 Combination Drugs
    5.1.4.1 Insulin Combinations
    5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
    5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
    5.1.4.2 Oral Combination
    5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
    5.2 Geography
    5.2.1 Europe
    5.2.1.1 United Kingdom (Value and Volume 2012-2024)
    5.2.1.1.1 Oral Anti-diabetic Drugs
    5.2.1.1.2 Insulin
    5.2.1.1.3 Non-insulin Injectable Drugs
    5.2.1.1.4 Combination Drugs
    5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.2 Germany (Value and Volume 2012-2024)
    5.2.1.2.1 Oral Anti-diabetic Drugs
    5.2.1.2.2 Insulin
    5.2.1.2.3 Non-insulin Injectable Drugs
    5.2.1.2.4 Combination Drugs
    5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.3 Italy (Value and Volume 2012-2024)
    5.2.1.3.1 Oral Anti-diabetic Drugs
    5.2.1.3.2 Insulin
    5.2.1.3.3 Non-insulin Injectable Drugs
    5.2.1.3.4 Combination Drugs
    5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.4 Spain (Value and Volume 2012-2024)
    5.2.1.4.1 Oral Anti-diabetic Drugs
    5.2.1.4.2 Insulin
    5.2.1.4.3 Non-insulin Injectable Drugs
    5.2.1.4.4 Combination Drugs
    5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.5 France (Value and Volume 2012-2024)
    5.2.1.5.1 Oral Anti-diabetic Drugs
    5.2.1.5.2 Insulin
    5.2.1.5.3 Non-insulin Injectable Drugs
    5.2.1.5.4 Combination Drugs
    5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.6 Russia (Value and Volume 2012-2024)
    5.2.1.6.1 Oral Anti-diabetic Drugs
    5.2.1.6.2 Insulin
    5.2.1.6.3 Non-insulin Injectable Drugs
    5.2.1.6.4 Combination Drugs
    5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)
    5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.1.7.1 Oral Anti-diabetic Drugs
    5.2.1.7.2 Insulin
    5.2.1.7.3 Non-insulin Injectable Drugs
    5.2.1.7.4 Combination Drugs
    5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck and others)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetic Population (2012-2024)
    6.2 Type-2 Diabetic Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 Company Profiles
    7.1.1 Takeda
    7.1.2 Pfizer
    7.1.3 Eli Lilly
    7.1.4 Janssen Pharmaceuticals
    7.1.5 Astellas
    7.1.6 Boehringer Ingelheim
    7.1.7 Merck and Co.
    7.1.8 AstraZeneca
    7.1.9 Bristol Myers Squibb
    7.1.10 Novartis
    7.1.11 Sanofi

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Edge Computing Market 2019 | Market Research by Latest Business Opportunities, Industry Share, Top Manufacturer, and Global Market Insight Forecast to 2024

    Anomaly Detection Market 2019 Evolving Technologies by Size and Share, Key Players Analysis, Sales Revenue, Growth Status, Opportunity Assessment and Business Expansion Plans 2024

    2019 Electronic Medical Records Market Share, Size, Growth Rate by Market Current Strategy, Top Most Players, and Regional Segmentation by Forecast to 2024

    2019-2024 Public Safety Market Explosive Outlook by Leading Players, Development Status, Source of Power, Estimated CAGR, and Forecast